Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges
Pharmaceutics · 16.01.2023 · 15 (1) · 298
DOI: 10.3390/pharmaceutics15010298 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 16.01.2023. Verfasst von Amanda Cano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ace Alzheimer Center Barcelona-International University of Catalunya (UIC), 08028 Barcelona, Spain. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII) grant Sara Borrell, Ministerio de Ciencia e Innovación, Proyectos de Generación de Conocimiento.
Abstract (Originalsprache)
Neurodegenerative diseases constitute a group of pathologies whose etiology remains unknown in many cases, and there are no treatments that stop the progression of such diseases. Moreover, the existence of the blood–brain barrier is an impediment to the penetration of exogenous molecules, including those found in many drugs. Exosomes are extracellular vesicles secreted by a wide variety of cells, and their primary functions include intercellular communication, immune responses, human reproduction, and synaptic plasticity. Due to their natural origin and molecular similarities with most cell types, exosomes have emerged as promising therapeutic tools for numerous diseases. Specifically, neurodegenerative diseases have shown to be a potential target for this nanomedicine strategy due to the difficult access to the brain and the strategy’s pathophysiological complexity. In this regard, this review explores the most important biological-origin drug delivery systems, innovative isolation methods of exosomes, their physicochemical characterization, drug loading, cutting-edge functionalization strategies to target them within the brain, the latest research studies in neurodegenerative diseases, and the future challenges of exosomes as nanomedicine-based therapeutic tools.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ace Alzheimer Center Barcelona-International University of Catalunya (UIC), 08028 Barcelona, Spain.
- Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), 28029 Madrid, Spain.
- Institute of Nanoscience and Nanotechnology (IN2UB), 08028 Barcelona, Spain.
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.
- Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, 08034 Barcelona, Spain.
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.
ORCID-Profile: Amanda Cano, Elena Sánchez-López, Miren Ettcheto, Eliana B Souto, Antonio Camins, Agustín Ruíz
Förderung
- Instituto de Salud Carlos III (ISCIII) grant Sara Borrell
- Ministerio de Ciencia e Innovación, Proyectos de Generación de Conocimiento
Zitieren
APA
Cano, A., Muñoz-Morales, Á., Sánchez-López, E., Ettcheto, M., Souto, E. B., Camins, A., Boada, M., & Ruíz, A. (2023). Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges. Pharmaceutics, 15(1), 298. https://doi.org/10.3390/pharmaceutics15010298
Vancouver
Cano A, Muñoz-Morales Á, Sánchez-López E, Ettcheto M, Souto EB, Camins A, et al. Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges. Pharmaceutics. 2023;15(1):298. doi:10.3390/pharmaceutics15010298
BibTeX
@article{Cano2023,
author = {Cano, Amanda and Muñoz-Morales, Álvaro and Sánchez-López, Elena and Ettcheto, Miren and Souto, Eliana B and Camins, Antonio and Boada, Mercè and Ruíz, Agustín},
title = {Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {1},
pages = {298},
doi = {10.3390/pharmaceutics15010298}
}
EUVIMED